Nephrogenic systemic fibrosis: A review

Journal of Drugs in Dermatology

Volumn 9, Issue 7, 2010, Pages 829-834

  Chen, Amy Y Y ^a   Zirwas, Matthew J ^b   Heffernan, Michael P ^c  

^a WRIGHT STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Central Dermatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CALCIPOTRIOL; CYCLOPHOSPHAMIDE; ETANERCEPT; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM PENTETATE; GADOTERIDOL; GADOVERSETAMIDE; IMATINIB; IMMUNOGLOBULIN; MESSENGER RNA; METHOTREXATE; METHOXSALEN; PENTOXIFYLLINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROCOLLAGEN; RETINOID; SODIUM THIOSULFATE; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRIAMCINOLONE;

AMYLOIDOSIS; BETA 2 MICROGLOBULIN AMYLOIDOSIS; CALCINOSIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; DERMATOFIBROSARCOMA PROTUBERANS; DIALYSIS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; EOSINOPHILIA MYALGIA SYNDROME; EOSINOPHILIC FASCIITIS; EXTRACORPOREAL PHOTOPHERESIS; HISTOPATHOLOGY; HUMAN; KIDNEY FUNCTION; LIPODERMATOSCLEROSIS; MORPHEA; MYXEDEMA; NEPHROGENIC SYSTEMIC FIBROSIS; PARANEOPLASTIC SYSTEMIC SCLEROSIS; PATHOGENESIS; PHOTODYNAMIC THERAPY; PHYSICAL DISABILITY; PLASMAPHERESIS; PUVA; REGULATORY T LYMPHOCYTE; RETICULATED ERYTHEMATOUS MUCINOSIS; REVIEW; SCLERODERMA; SCLEROMYXEDEMA; STEROID THERAPY; TOXIC OIL SYNDROME; PATHOLOGY;

HUMANS; NEPHROGENIC FIBROSING DERMOPATHY;

EID: 77955911563     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356(9234):1000-1001.
2. Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001;23(5):383-393. (Pubitemid 32938907)
3. Cowper SE, Bucala R, Leboit PE. Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis-Setting the record straight. Semin Arthritis Rheum. 2006;35(4):208-210. (Pubitemid 43185212)
4. Cowper SE. Nephrogenic Fibrosing Dermopathy. 2001-2009. Available at http://www.icnfdr.org. Accessed April 10, 2010.
5. Mackay-Wiggan JM, Cohen DJ, Hardy MA, et al. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol. 2003;48(1):55-60. (Pubitemid 36091534)
6. Swartz RD, Crofford LJ, Phan SH, et al. Nephrogenic fibrosing dermopathy: A novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114(7):563-572. (Pubitemid 36577259)
7. Cowper SE. Nephrogenic fibrosing dermopathy: The first 6 years. Curr Opin Rheumatol. 2003;15(6):785-790. (Pubitemid 38156308)
8. Panda S, Bandyopadhyay D, Tarafder A. Nephrogenic fibrosing dermopathy: A series in a non-Western population. J Am Acad Dermatol. 2006;54(1):155-159. (Pubitemid 41832479)
9. Jain SM, Wesson S, Hassanein A, et al. Nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol. 2004;19(4):467- 470.
10. Jan F, Segal JM, Dyer J, et al. Nephrogenic fibrosing dermopathy: Two pediatric cases. J Pediatr. 2003;143(5):678-681. (Pubitemid 37452802)
11. Auron A, Shao L, Warady BA. Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol. 2006;21(9):1307-1311. (Pubitemid 44203458)
12. Tan AW, Tan SH, Lian TY, et al. A case of nephrogenic fibrosing dermopathy. Ann Acad Med Singapore. 2004;33(4):527-529. (Pubitemid 39280144)
13. Markus JS, James AJ, Nunez-Gussman JK, et al. Nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2005;52(1):166-167.
14. Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: An update. Curr Rheumatol Rep. 2006;8(2):151-157. (Pubitemid 44623984)
15. Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med. 2006;145(3):234-235. (Pubitemid 46780577)
16. Fazeli A, Lio PA, Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? Arch Dermatol. 2004;140(11):1401. (Pubitemid 39473646)
17. Evenepoel P, Zeegers M, Segaert S, et al. Nephrogenic fibrosing dermopathy: A novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant. 2004;19(2):469-473. (Pubitemid 38196001)
18. Grobner T. Gadolinium - A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21(4):1104-1108.
19. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. AJR Am J Roentgenol. 2007;188(2):586-592. (Pubitemid 46167763)
20. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: A population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2(2):264-267.
21. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243(1):148-157. (Pubitemid 46579705)
22. Lauenstein TC, Salman K, Morreira R, et al. Nephrogenic systemic fibrosis: Center case review. J Magn Reson Imaging. 2007;26(5):1198-1203. (Pubitemid 350058286)
23. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast- enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17(9):2359-2362. (Pubitemid 44300951)
24. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: A summary of the medical literature reporting. Eur J Radiol. 2008;66(2):230-234.
25. Cowper SE. Gadolinium - Is it to blame? J Cutan Pathol. 2008;35(5):520-522. (Pubitemid 351519401)
26. Edward M, Quinn JA, Mukherjee S, et al. Gadodiamide contrast agent 'activates' fibroblasts: A possible cause of nephrogenic systemic fibrosis. J Pathol. 2008;214(5):584-593. (Pubitemid 351482273)
27. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: A possible role for gadolinium-based contrast media. Invest Radiol. 2008;43(1):65-75.
28. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: Suspect identified, motive unclear. Am J Dermatopathol. 2003;25(4):358. (Pubitemid 36897345)
29. Quan TE, Cowper S, Wu SP, et al. Circulating fibrocytes: Collagensecreting cells of the peripheral blood. Int J Biochem Cell Biol. 2004;36(4):598-606. (Pubitemid 38316817)
30. Ortonne N, Lipsker D, Chantrel F, et al. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: A new pathogenic hypothesis. Br J Dermatol. 2004;150(5):1050-1052. (Pubitemid 38903558)
31. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: Insights from two cases and review of the recent literature. Am J Transplant. 2007;7(10):2425- 2432.
32. Anavekar NS, Chong AH, Norris R, et al. Nephrogenic systemic fibrosis in a gadolinium-naive renal transplant recipient. Australas J Dermatol. 2008;49(1):44-47.
33. Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol. 2008;66(2):191- 199.
34. Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve. 2004;30(5):569-577. (Pubitemid 39447280)
35. Kim RH, Ma L, Hayat SQ, et al. Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis in 2 patients with end-stage renal disease on hemodialysis. J Clin Rheumatol. 2006;12(3):134-136. (Pubitemid 44314973)
36. Schmook T, Budde K, Ulrich C, et al. Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant. 2005;20(1):220- 222.
37. Pryor JG, Poggioli G, Galaria N, et al. Nephrogenic systemic fibrosis: A clinicopathologic study of six cases. J Am Acad Dermatol. 2007;57(1):105-111. (Pubitemid 46899273)
38. Cheung PP, Dorai Raj AK. Nephrogenic fibrosing dermopathy: A new clinical entity mimicking scleroderma. Intern Med J. 2007;37(2):139-141. (Pubitemid 46066630)
39. Bangsgaard N, Marckmann P, Rossen K, et al. Nephrogenic systemic fibrosis: late skin manifestations. Arch Dermatol. 2009;145(2):183- 187.
40. Gilliet M, Cozzio A, Burg G, et al. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol. 2005;152(3):531-536. (Pubitemid 40547128)
41. Streams BN, Liu V, Liegeois N, et al. Clinical and pathologic features of nephrogenic fibrosing dermopathy: A report of two cases. J Am Acad Dermatol. 2003;48(1):42-47. (Pubitemid 36091532)
42. Saenz A, Mandal R, Kradin R, et al. Nephrogenic fibrosing dermopathy with involvement of the dura mater. Virchows Arch. 2006;449(3):389-391. (Pubitemid 44367984)
43. Kafi R, Fisher GJ, Quan T, et al. UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol. 2004;140(11):1322- 1324.
44. Lauchli S, Zortea-Caflisch C, Nestle FO, et al. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology. 2004;208(3):278-280. (Pubitemid 38594553)
45. DiCarlo JB, Gupta EA, Solomon AR. A pediatric case of nephrogenic fibrosing dermopathy: Improvement after combination therapy. J Am Acad Dermatol. 2006;54(5):914-916.
46. Introcaso CE, Hivnor C, Cowper S, et al. Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis: A case series of nine patients and review of the literature. Int J Dermatol. 2007;46(5):447- 452.
47. Scheinfeld N. Nephrogenic fibrosing dermopathy: A comprehensive review for the dermatologist. Am J Clin Dermatol. 2006;7(4):237- 247.
48. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum. 2004;50(8):2660-2666. (Pubitemid 39062729)
49. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis: Report of a new case with literature review. Am J Kidney Dis. 2005;46(4):754-759. (Pubitemid 41383955)
50. Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: An autopsy case and review of the literature. Arch Pathol Lab Med. 2006;130(2):209-212. (Pubitemid 43237993)
51. Gremmels JM, Kirk GA. Two patients with abnormal skeletal muscle uptake of Tc-99m hydroxymethylene diphosphonate following liver transplant: Nephrogenic fibrosing dermopathy and graft vs host disease. Clin Nucl Med. 2004;29(11):694-697. (Pubitemid 39410813)
52. Bardin T. Musculoskeletal manifestations of chronic renal failure. Curr Opin Rheumatol. 2003;15(1):48-54. (Pubitemid 36021023)
53. LeBoit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol. 2003;139(7):928-930. (Pubitemid 36898932)
54. Ting WW, Stone MS, Madison KC, et al. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139(7):903-906. (Pubitemid 36898926)
55. Kucher C, Steere J, Elenitsas R, et al. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol. 2006;54(2 Suppl):S31-S34. (Pubitemid 43113084)
56. Richmond H, Zwerner J, Kim Y, et al. Nephrogenic systemic fibrosis: Relationship to gadolinium and response to photopheresis. Arch Dermatol. 2007;143(8):1025-1030. (Pubitemid 47296079)
57. Nampoory MR, Das KC, Johny KV, et al. Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation. Am J Kidney Dis. 2003;42(4):797-805. (Pubitemid 37187381)
58. Molino D, De Lucia D, Gaspare De Santo N. Coagulation disorders in uremia. Semin Nephrol. 2006;26(1):46-51. (Pubitemid 43075511)
59. Hubbard V, Davenport A, Jarmulowicz M, et al. Scleromyxoedema- like changes in four renal dialysis patients. Br J Dermatol. 2003;148(3):563-568. (Pubitemid 36461338)
60. Ruiz-Genao DP, Pascual-Lopez MP, Fraga S, et al. Osseous metaplasia in the setting of nephrogenic fibrosing dermopathy. J Cutan Pathol. 2005;32(2):172-175. (Pubitemid 40216056)
61. Hershko K, Hull C, Ettefagh L, et al. A variant of nephrogenic fibrosing dermopathy with osteoclast-like giant cells: A syndrome of dysregulated matrix remodeling? J Cutan Pathol. 2004;31(3):262-265. (Pubitemid 38230569)
62. Kucher C, Xu X, Pasha T, et al. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol. 2005;32(7):484-490. (Pubitemid 41039398)
63. Solomon GJ, Wu E, Rosen PP. Nephrogenic systemic fibrosis mimicking inflammatory breast carcinoma. Arch Pathol Lab Med. 2007;131(1):145-148. (Pubitemid 46174151)
64. Edsall LC, English JC, 3rd, Teague MW, et al. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol. 2004;31(3):247-253. (Pubitemid 38230567)
65. Lewis KG, Lester BW, Pan TD, et al. Nephrogenic fibrosing dermopathy and calciphylaxis with pseudoxanthoma elasticum-like changes. J Cutan Pathol. 2006;33(10):695-700. (Pubitemid 44536350)
66. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56(1):21-26. (Pubitemid 46017000)
67. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007;56(1):27-30. (Pubitemid 44969309)
68. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56(4):710-712. (Pubitemid 46400200)
69. Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: Early recognition and treatment. Semin Dial. 2008;21(2):123-128.
70. DeHoratius DM, Cowper SE. Nephrogenic systemic fibrosis: An emerging threat among renal patients. Semin Dial. 2006;19(3):191- 194.
71. Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol. 2003;25(3):204-209. (Pubitemid 36706461)
72. Chung HJ, Chung KY. Nephrogenic fibrosing dermopathy: Response to high-dose intravenous immunoglobulin. Br J Dermatol. 2004;150(3):596-597.
73. Marckmann P, Nielsen AH, Sloth JJ. Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2008;23(10):3280-3282.
74. Yerram P, Saab G, Karuparthi PR, et al. Nephrogenic systemic fibrosis:A mysterious disease in patients with renal failure-Role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol. 2007;2(2):258-263.
75. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91(9):4082- 4085.
76. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173(3):699-703.
77. Mesa RA, Elliott MA, Schroeder G, et al. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc. 2004;79(7):883-889. (Pubitemid 38879954)
78. Moschella SL, Kay J, Mackool BT, et al. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med. 2004;351(21):2219-2227.
79. Scheinfeld NS, Cowper SE. Nephrogenic fibrosing dermopathy. Emedicine dermatology chapter [online]. Available at http://www. emedicine.com/DERM/ topic934.htm. Accessed July 28, 2008.
80. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561-566.
81. Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004;114(9):1308-1316. (Pubitemid 40385302)
82. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008;58(8):2543-2548.
83. Clinicaltrials.gov. Available at http://www.clinicaltrials.gov/ct2/ show/NCT00677092?term=Nephrogenic+systemic+fibrosis+AN D+Gleevec&rank=1. Accessed April 05, 2009.
84. Mathur K, Morris S, Deighan C, et al. Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: Three case reports and review of literature. J Clin Apher. 2008;23(4):144-150.
85. Lauchli S, Zortea-Caflisch C, Nestle FO, et al. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology. 2004;208(3):278-280. (Pubitemid 38594553)